TABLE 2.

Predictors of CRP levels in patients with MINOCA

	Model 1 (n = 9716)		Model 2 (n = 8061)		Model 3 (n = 4098)
	β	p value	β	p value	β	p value
Age (10 years)	0.042	.001	0.025	.070	0.072	<.001
Male sex	0.019	.056	0.020	.070	0.009	0.557
Current smoking	0.061	<.001	0.052	<.001	0.067	<.001
Hypertension	−0.001	0.962	0.006	0.655	0.018	0.372
Diabetes	0.061	<.001	0.053	<.001	0.072	<.001
Hyperlipidemia	0.029	0.567	0.037	0.514	0.211	.011
eGFR	−0.075	<.001	−0.053	<.001	−0.033	.070
Heart failure	0.025	.016	‐	‐	0.015	0.347
Previous stroke	0.001	0.928	−0.006	0.615	−0.009	0.560
PAD	0.056	<.001	0.068	<.001	0.069	<.001
COPD	0.103	<.001	0.090	<.001	0.122	<.001
Previous/present cancer	0.030	.003	0.030	.006	0.046	.002
Dementia	−0.010	0.288	−0.002	0.835	−0.014	0.351
Atrial fibrillation	0.042	<.001	0.040	.001	0.043	.009
LVEF	‐	‐	0.115	<.001	‐	‐
hs‐cTnT (ln)	‐	‐	‐	‐	0.111	<.001

Abbreviations: COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; LVEF, left‐ventricular ejection fraction; hs‐cTnT: high‐sensitivity cardiac troponin T; PAD, peripheral artery disease.

Note: Model 1: Analyses were adjusted for all assessed variables, medications at admission (as listed in Table 1), hospital and admission year. Model 2: adjusted as model 1 with replacement of heart failure by left‐ventricular ejection fraction, categorized as ≥0.50, 0.40–0.49, 0.30–0.39 and < 0.30. Model 3: adjusted as model 1 with additional adjustment for high‐sensitivity cardiac troponin T (ln).